$NBP

$1.26 +$0.01 (0.4%) Close

$NBP Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 265.4M shares outstanding

Who owns NBP?

By type of holder

Institutions 9.3% Insiders 0.0% Everyone else 90.7%

Concentration Top 10 holders own 27.5%

Everest Medicines Limited 16.0% · CBC Investment I-Mab Limited 4.4%

Institutional ownership

9.3%

-1.8 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

−4.7M

by institutions in Q2 2026

New / sold out

13 / 13

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Marshall Wace, LLP NEW +1.2M
Two Sigma Investments, LP NEW +851.3K

Biggest sellers in Q2 2026

Janus Henderson Group PLC SOLD OUT −6.0M
Point72 Asset Management, L.P. SOLD OUT −1.4M

Who is planning to sell?

Notices of proposed sale, last 12 months

$648K

6 notices from 3 people

Shares covered

186.9K

0.07% of the company

Arranged in advance

80%

of the value is under a 10b5-1 plan

Under a 10b5-1 plan No plan

Largest proposed sellers

Skelton Joseph W. Officer 10b5-1 $520K
Cao Sean Wuxiong Officer $97.9K

Every notice on Red Flags →

A Form 144 is notice of a planned sale, not the sale itself. What insiders actually sold is on Insider Transactions.

Is your stake being diluted?

Diluted share count, FY2017–FY2025

+3735.5%

+57.75% a year

Each share's claim on the business

−97.4%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $1.51B

over 9 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years40% 3–5 years2% 1–3 years6% Under 1 year52%

Quarterly turnover

24.8%

of institutional shares changed hands

Top 10 managers, median time held

3 quarters

Super Investors

Investment managers reporting NBP on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
JH Janus Henderson Group PLC	—	—	SOLD OUT	—	0.0%
Shares held by quarter Peak holding8.4M (Q4'25) Change over 8 quarters0 Janus Henderson Group PLC's full portfolio →
HA HHLR Advisors, LTD.	6.0M	2.25%	Unchanged	≤2021	1.4%
Shares held by quarter Peak holding6.9M (Q3'24) Change over 8 quarters−928.7K Share of the company2.250% HHLR Advisors, LTD.'s full portfolio →

Janus Henderson Group PLC

—

% of company

—

Change vs last qtr

SOLD OUT

Held since

—

HHLR Advisors, LTD.

6.0M

% of company

2.25%

Change vs last qtr

Unchanged

Held since

≤2021

28 more super investors behind a free account

See every manager holding NovaBridge Biosciences, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting NBP on Form N-PORT; together they hold 0.5% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
IB iShares Biotechnology ETF iShares Trust	$1.15M	591.4K	0.22%	0.01%	June 30, 2026
SS State Street(R) SPDR(R) Portfolio Emerging Markets ETF SPDR Index Shares Funds	$581K	297.8K	0.11%	0.00%	June 30, 2026

iShares Biotechnology ETF

iShares Trust

Position value

$1.15M

% of company

0.22%

% of the fund

0.01%

As of

June 30, 2026

State Street(R) SPDR(R) Portfolio Emerging Markets ETF

SPDR Index Shares Funds

Position value

$581K

% of company

0.11%

% of the fund

0.00%

As of

June 30, 2026

13 more funds behind a free account

See every fund holding NovaBridge Biosciences and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
EM Everest Medicines Limited 5%+ holder 13D · 16.1%	42.5M	16.02%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company16.020% Disclosed stake13D · 16.1% View the 13D/G filing →
CI CBC Investment I-Mab Limited 5%+ holder 13D · 4.4%	11.8M	4.44%	—	—	—	—
This holder reports through Schedule 13D/G, not a quarterly 13F. Share of the company4.440% Disclosed stake13D · 4.4% View the 13D/G filing →

Everest Medicines Limited

5%+ holder13D · 16.1%

42.5M

% of company

16.02%

Change vs last qtr

—

Held since

—

CBC Investment I-Mab Limited

5%+ holder13D · 4.4%

11.8M

% of company

4.44%

Change vs last qtr

—

Held since

—

Comments